Form 4: BioCryst Pharmaceuticals Executive Reports Tax Withholding Transaction
SEC Form 4 Filing
Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to vested Restricted Stock Units.
Summary
- On March 31, 2024, Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, engaged in a transaction where 7,525 shares of common stock were withheld by the issuer to satisfy tax withholding obligations.
- The price per share for the transaction was $5.08.
- Following the transaction, Thackray directly owns 242,139 shares of BioCryst Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, with no inherent positive or negative implications for the company's performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their holdings in the company's stock.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine tax-related activity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2024 | Date of transaction (share withholding for tax obligations). |
| 04/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.